Status and phase
Conditions
Treatments
About
This is an interventional trial. The goal of this clinical trial is dose finding. There are two phases: phase Ib to determine the MTD and recommended phase II dose of niraparib in combination with abemaciclib in patients with advanced ovarian cancer.
Target population will be patients (woman, age > 18 years) with epithelial ovarian, fallopian tube or peritoneal cancer treated with at least 2 lines of therapy.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
NOTE: if archived tissue is not available, patient must be willing to undergo a tumor biopsy at screening if medically feasible.
The methods that can achieve a failure rate of less than 1% per year when used consistently and correctly are considered as highly effective birth control methods. Such methods include:
combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:
progestogen-only hormonal contraception associated with inhibition of ovulation:
intrauterine device (IUD);
intrauterine hormone-releasing system (IUS);
bilateral tubal occlusion;
vasectomised partner;
sexual abstinence.
Additional inclusion criteria:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
73 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal